“Its spectacular, my husband has this variation called LRRK 2,” she said.Academics “jaws dropped” when they found out 23andMe had made a discovery of that caliber, she said. Thats because most pharmaceutical companies keep data close to the chest so they retain a competitive advantage over other companies, she said.”Through the research is the first time that consumers having participant driven research, weve been able to identify the gene SGK1 that looks like its a modifier and protecting against LRRK2 a gene associated with increased risk of Parkinsons,” 23andMe founder Anne Wojcicki said. “The community has been so successful that in such a short time frame we found something that could be a modifier that could lead to a druggable target.”
via Sergey Brins Wife Might Have Figured Out A Way To Save His Life.